Ford HL - Search Results

1

Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents.

Menke C, Bin L, Thorburn J, Behbakht K, Ford HL, Thorburn A. Menke C, et al. Among authors: ford hl. Cancer Res. 2011 Mar 1;71(5):1883-92. doi: 10.1158/0008-5472.CAN-10-2252. Cancer Res. 2011. PMID: 21363923 Free PMC article.

2

Gene amplification is a mechanism of Six1 overexpression in breast cancer.

Reichenberger KJ, Coletta RD, Schulte AP, Varella-Garcia M, Ford HL. Reichenberger KJ, et al. Among authors: ford hl. Cancer Res. 2005 Apr 1;65(7):2668-75. doi: 10.1158/0008-5472.CAN-04-4286. Cancer Res. 2005. PMID: 15805264

3

Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival.

Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A, Ford HL. Behbakht K, et al. Among authors: ford hl. Cancer Res. 2007 Apr 1;67(7):3036-42. doi: 10.1158/0008-5472.CAN-06-3755. Cancer Res. 2007. PMID: 17409410

4

TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.

Thorburn A, Behbakht K, Ford H. Thorburn A, et al. Drug Resist Updat. 2008 Feb-Apr;11(1-2):17-24. doi: 10.1016/j.drup.2008.02.001. Epub 2008 Apr 18. Drug Resist Updat. 2008. PMID: 18374623 Free PMC article. Review.

5

Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation.

Coletta RD, Christensen KL, Micalizzi DS, Jedlicka P, Varella-Garcia M, Ford HL. Coletta RD, et al. Among authors: ford hl. Cancer Res. 2008 Apr 1;68(7):2204-13. doi: 10.1158/0008-5472.CAN-07-3141. Cancer Res. 2008. PMID: 18381426

6

Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth.

Micalizzi DS, Wang CA, Farabaugh SM, Schiemann WP, Ford HL. Micalizzi DS, et al. Among authors: ford hl. Cancer Res. 2010 Dec 15;70(24):10371-80. doi: 10.1158/0008-5472.CAN-10-1354. Epub 2010 Nov 5. Cancer Res. 2010. PMID: 21056993 Free PMC article.

7

TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro.

Menke C, Goncharov T, Qamar L, Korch C, Ford HL, Behbakht K, Thorburn A. Menke C, et al. Among authors: ford hl. PLoS One. 2011 Jan 14;6(1):e14527. doi: 10.1371/journal.pone.0014527. PLoS One. 2011. PMID: 21264287 Free PMC article.

8

Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer.

Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K. Qamar L, et al. Among authors: ford hl. Gynecol Oncol. 2012 May;125(2):451-7. doi: 10.1016/j.ygyno.2012.02.007. Epub 2012 Feb 12. Gynecol Oncol. 2012. PMID: 22333994 Free PMC article.

9

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.

Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. Dimberg LY, et al. Among authors: ford hl. Oncogene. 2013 Mar 14;32(11):1341-50. doi: 10.1038/onc.2012.164. Epub 2012 May 14. Oncogene. 2013. PMID: 22580613 Free PMC article. Review.

10

Molecular pathways: targeting the TGF-β pathway for cancer therapy.

Smith AL, Robin TP, Ford HL. Smith AL, et al. Among authors: ford hl. Clin Cancer Res. 2012 Sep 1;18(17):4514-21. doi: 10.1158/1078-0432.CCR-11-3224. Epub 2012 Jun 18. Clin Cancer Res. 2012. PMID: 22711703 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

154 results

Search Page

Filters